DLA Piper advises RQM+ on acquisition of CRO Kottmann

DLA Piper has advised RQM+, a global leader in MedTech services, on the acquisition of CRO Dr. med. Kottmann GmbH & Co. KG, a leading contract research organization (CRO) based in Germany.

This strategic acquisition will expand RQM+’s presence in Europe and ensure comprehensive end-to-end support for clients, from pre-clinical phases to product commercialization. The addition of CRO Kottmann further expands RQM+'s rapidly growing business as a leading MedTech company, driving both existing and new clients’ innovations into pivotal markets. RQM+ currently works with 19 of the top 20 medical device companies and 7 of the top 10 IVD companies.

CRO Kottmann is an international clinical research organization that conducts clinical studies with medical devices, in vitro diagnostics and pharmaceuticals. RQM+ is the world's leading MedTech service provider offering consulting, clinical trial, lab, and reimbursement services, as well as technology solutions to support the entire product lifecycle.

The DLA Piper team was led by partner Lars Jessen and counsel Till Burmeister (both M&A/Private Equity, Frankfurt/Hamburg). US partner Alex Plakas advised on aspects of US law together with associates Edwin Cruz and Daniel Cho (all Chicago). In addition, partners Dr Henriette Norda (Employment, Hamburg) and Semin O (Antitrust, Frankfurt), counsel Dr Nico Brunotte (IP/IT, Hamburg), Georg Haberkorn (Employment, Munich), Dr Thilo Streit (Public Commercial Law, Cologne) and Lukas Weidner (Real Estate, Cologne), senior associates Louisa Arlette Maier-Witt (Antitrust, Hamburg) and Annika Heinz (Employment, Munich) and associates Marc Großmann (Corporate/M&A, Hamburg) and Lara Joy Pabst (M&A/Private Equity, Frankfurt), Hannah Modi (Employment, Hamburg), Julia Goetzendorff (Antitrust, Cologne) and Vincent Wehner (Real Estate, Munich) were involved.